Comparative Pharmacology
Head-to-head clinical analysis: DRALZINE versus EXFORGE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRALZINE versus EXFORGE.
DRALZINE vs EXFORGE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Exforge is a combination of amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine inhibits calcium influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation. Valsartan selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation and reduced aldosterone secretion.
Oral: 50-100 mg twice daily; maximum 200 mg/day.
One tablet orally once daily. Initial dose: 5/160 mg or 5/320 mg. Titrate based on blood pressure response. Maximum dose: 10/320 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
Amlodipine: terminal elimination half-life is 30-50 hours (mean ~35 h), supporting once-daily dosing. Valsartan: terminal half-life is approximately 6 hours, with the combination product dosed once daily due to amlodipine's long half-life.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Valsartan is primarily eliminated via biliary excretion (83%) in feces as unchanged drug; renal excretion accounts for 13% (mostly unchanged). Amlodipine is extensively metabolized in the liver, with 60% of metabolites excreted renally and 20-25% in feces as unchanged drug.
Category C
Category C
Antihypertensive
Antihypertensive